Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells
Jiao Wang, Sandra Toregrosa-Allen, Bennett D. Elzey, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 45
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Guanghe Ran, Yu qing Lin, Lei Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 140
NK cells and solid tumors: therapeutic potential and persisting obstacles
Le Tong, Carlos Jiménez‐Cortegana, Apple H.M. Tay, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 88
Forks in the road for CAR T and CAR NK cell cancer therapies
Oula K. Dagher, Avery D. Posey
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 1994-2007
Closed Access | Times Cited: 47
Chemically engineering cells for precision medicine
Yixin Wang, Zhaoting Li, Fanyi Mo, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 3, pp. 1068-1102
Closed Access | Times Cited: 40
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
Wenkang Wang, Yang Liu, Zhen He, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 36
Glioblastoma Microenvironment and Cellular Interactions
Carmen Crivii, Adina Bianca Boşca, Carmen Stanca Melincovici, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1092-1092
Open Access | Times Cited: 44
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Marisa K. Kilgour, Donald Bastin, Seung‐Hwan Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 34
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zhibo Zheng, Siyuan Li, Mohan Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3476-3476
Open Access | Times Cited: 26
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Yalan Zhang, Weilin Zhou, Jianping Yang, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 25
Advances in NK cell therapy for brain tumors
Jawad Fares, Zachary Davis, Julian S. Rechberger, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 22
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
Kyle B. Lupo, Xue Yao, Shambhavi Borde, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma
Nian Chen, Cheng Peng, Dan Li
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
Oula El Atat, Rayan Naser, Maya Abdelkhalek, et al.
Oncology Letters (2022) Vol. 25, Iss. 2
Open Access | Times Cited: 27
B7-H3 in Brain Malignancies: Immunology and Immunotherapy
Xiaopeng Guo, Mengqi Chang, Yu Wang, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 12, pp. 3762-3780
Open Access | Times Cited: 20
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Ye Li, Katayoun Rezvani, Hind Rafei
Immunological Reviews (2023) Vol. 320, Iss. 1, pp. 217-235
Open Access | Times Cited: 20
CAR-NK cell therapy for glioblastoma: what to do next?
Qi Xiong, Jiao Zhu, Yong Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 16
Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes
Teding Chang, Yu-Jie Chen, Jialiu Luo, et al.
ImmunoTargets and Therapy (2025) Vol. Volume 14, pp. 99-121
Open Access
The Role of TIM-3 in Glioblastoma Progression
Farah Ahmady, Amit Sharma, Adrian Achuthan, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 346-346
Open Access
Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma
Minjie Wang, Zijie Zhou, Xuan Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 22
Therapeutic utility of engineered myeloid cells in the tumor microenvironment
Alessandro Canella, Prajwal Rajappa
Cancer Gene Therapy (2023) Vol. 30, Iss. 7, pp. 964-972
Open Access | Times Cited: 12
Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy
Zhicheng Jin, Xuefeng Sun, Yaoyao Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations
Payal Aggarwal, Wen Luo, Katherine C. Pehlivan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities
Shambhavi Borde, Sandro Matosevic
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 832-848
Closed Access | Times Cited: 11
Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
Chinmayee Dash, Dhruba Sonowal, Prachi Dhaka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
Xinyu Wu, Sandro Matosevic
Molecular Therapy — Oncolytics (2022) Vol. 27, pp. 224-238
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top